April 25, 2012 / 5:25 AM / 6 years ago

Novartis gets EU approval for Cushing's drug

ZURICH, April 25 (Reuters) - Swiss drugmaker Novartis AG NOVN.VX said on Wednesday it has won European Union approval for its Signifor as the first medical therapy for Cushing’s disease, a rare hormonal disorder.

Signifor, which is designed for Cushing’s disease patients who cannot have surgery or for whom surgery has not been successful, had already won a green light from the European Medicines Agency (EMA) in January. [ID:nL6E8CK24E]

Cushing’s is caused by a small tumour of the pituitary gland making too much of a hormone. Standard treatment is surgical removal of the tumour, but this does not always work.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below